No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Small-cap biotech drawdowns present mispriced entry points
The speaker argued that severe drawdowns in small-cap biotech stocks are predominantly driven by small-cap beta and cash runway fears rather than deteriorating scientific fundamentals.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.